The impact of tirzepatide on clinical kidney outcomes is part of the SURPASS CVOT (T2D patients) and multimorbidity outcomes (people with overweight or obesity without T2D) (91), albeit as secondary endpoints
Currently, GLP-1 receptor agonists should only be used for FDA-approved indications such as type 2 diabetes or obesity
Episodes that resolve on their own can still be warning signs, particularly if youre unsure what caused them
Since the discovery that GLP-1 can improve insulin secretion and glycemic control in patients with type 2 diabetes mellitus (T2DM) in the 1990s (Nauck et al., 1993
Furthermore, undiagnosed conditions such as hypothyroidism or Cushing's syndrome can impair weight loss and glycaemic control regardless of GLP-1 treatment
Enhanced Formulations: By adding supportive ingredients, we can create a formula that not only aids in weight loss but also boosts your energy and overall well-being